In the first known study of its kind, an article published in the August 1st issue of the journal SLEEP finds that children with attention deficit hyperactivity disorder (ADHD), and whose sleep efficiency is poor, experience significant improvement on some measures of the Continuous Performance Test (CPT) if they are treated with methylphenidate (MPH).

Shire plc announced that DAYTRANAâ„¢ (methylphenidate transdermal system), its Attention Deficit Hyperactivity Disorder (ADHD) patch, had significant efficacy in reducing the symptoms of ADHD in both male and female children aged 6 to 12 years, according to clinical trial results reported at the American Psychiatric Association (APA) annual meeting in San Diego.